Sanofi SA (SNY)
48.28
+0.30
(+0.63%)
USD |
NASDAQ |
Nov 22, 16:00
48.35
+0.07
(+0.14%)
After-Hours: 20:00
Sanofi Revenue (TTM): 53.04B for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 53.04B |
| June 30, 2024 | 51.29B |
| March 31, 2024 | 50.69B |
| December 31, 2023 | 50.28B |
| September 30, 2023 | 48.85B |
| June 30, 2023 | 48.26B |
| March 31, 2023 | 48.06B |
| December 31, 2022 | 47.67B |
| September 30, 2022 | 47.87B |
| June 30, 2022 | 47.40B |
| March 31, 2022 | 46.86B |
| December 31, 2021 | 46.29B |
| September 30, 2021 | 43.67B |
| June 30, 2021 | 41.18B |
| March 31, 2021 | 41.37B |
| June 30, 2020 | 41.70B |
| March 31, 2020 | 42.49B |
| December 31, 2019 | 42.11B |
| September 30, 2019 | 41.66B |
| June 30, 2019 | 41.96B |
| March 31, 2019 | 41.99B |
| December 31, 2018 | 42.08B |
| September 30, 2018 | 42.04B |
| June 30, 2018 | 41.75B |
| March 31, 2018 | 41.45B |
| Date | Value |
|---|---|
| December 31, 2017 | 40.95B |
| September 30, 2017 | 40.24B |
| June 30, 2017 | 39.57B |
| March 31, 2017 | 39.13B |
| December 31, 2016 | 38.39B |
| September 30, 2016 | 35.98B |
| June 30, 2016 | 36.36B |
| March 31, 2016 | 36.66B |
| December 31, 2015 | 37.19B |
| September 30, 2015 | 38.53B |
| June 30, 2015 | 39.53B |
| March 31, 2015 | 41.02B |
| December 31, 2014 | 42.60B |
| September 30, 2014 | 42.67B |
| June 30, 2014 | 42.21B |
| March 31, 2014 | 41.60B |
| December 31, 2013 | 41.51B |
| September 30, 2013 | 43.86B |
| June 30, 2013 | 44.12B |
| March 31, 2013 | 45.26B |
| December 31, 2012 | 46.21B |
| September 30, 2012 | 47.00B |
| June 30, 2012 | 48.41B |
| March 31, 2012 | 49.34B |
| December 31, 2011 | 48.83B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
41.18B
Minimum
Jun 2021
53.04B
Maximum
Sep 2024
46.62B
Average
47.54B
Median
Revenue (TTM) Benchmarks
| AstraZeneca PLC | 51.21B |
| GSK PLC | 39.71B |
| Eli Lilly and Co | 40.86B |
| Novavax Inc | 847.25M |
| Regeneron Pharmaceuticals Inc | 13.85B |